ST1326 (teglicar) is a preclinical-stage CPT1 inhibitor with demonstrated antitumor effects, particularly when combined with Bcl-2 inhibitors (e.g., ABT199) in acute myeloid leukemia (AML) [139–142]. Here, BCL2 is linked to acute myeloid leukemia.